660 related articles for article (PubMed ID: 7563486)
21. Mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A (Sipple's syndrome).
Oishi S; Sato T; Takiguchi-Shirahama S; Nakamura Y
Endocr J; 1995 Aug; 42(4):527-36. PubMed ID: 8556060
[TBL] [Abstract][Full Text] [Related]
22. [Detection of RET-proto-oncogene mutations in the diagnosis of Type 2 endocrine neoplasia (MEN 2)].
Komminoth P; Muletta-Feurer S; Soltermann A; Gemsenjäger E; Bürgi H; Staub JJ; Schönle E; Fried M; Vetter W; Spinas GA; Heitz PU
Schweiz Med Wochenschr; 1996 Aug; 126(31-32):1329-38. PubMed ID: 8765374
[TBL] [Abstract][Full Text] [Related]
23. Molecular and biochemical screening for the diagnosis and management of medullary thyroid carcinoma in multiple endocrine neoplasia type 2A.
Vieira AE; Mello MP; Elias LL; Lau IF; Maciel LM; Moreira AC; Castro M
Horm Metab Res; 2002 Apr; 34(4):202-6. PubMed ID: 11987030
[TBL] [Abstract][Full Text] [Related]
24. Very early detection of RET proto-oncogene mutation is crucial for preventive thyroidectomy in multiple endocrine neoplasia type 2 children: presence of C-cell malignant disease in asymptomatic carriers.
Sanso GE; Domene HM; Garcia R; Pusiol E; de M; Roque M; Ring A; Perinetti H; Elsner B; Iorcansky S; Barontini M
Cancer; 2002 Jan; 94(2):323-30. PubMed ID: 11900218
[TBL] [Abstract][Full Text] [Related]
25. Isolated familial pheochromocytoma as a variant of von Hippel-Lindau disease.
Ritter MM; Frilling A; Crossey PA; Höppner W; Maher ER; Mulligan L; Ponder BA; Engelhardt D
J Clin Endocrinol Metab; 1996 Mar; 81(3):1035-7. PubMed ID: 8772572
[TBL] [Abstract][Full Text] [Related]
26. Low frequency of germline mutations in the RET proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma.
Eng C; Mulligan LM; Smith DP; Healey CS; Frilling A; Raue F; Neumann HP; Ponder MA; Ponder BA
Clin Endocrinol (Oxf); 1995 Jul; 43(1):123-7. PubMed ID: 7641404
[TBL] [Abstract][Full Text] [Related]
27. Multiple endocrine neoplasia type 2A with the identical somatic mutation in medullary thyroid carcinoma and pheochromocytoma without germline mutation at the corresponding site in the RET proto-oncogene.
Akama H; Noshiro T; Kimura N; Shimizu K; Watanabe T; Shibukawa S; Nakai S; Miura W; Ito S; Miura Y
Intern Med; 1999 Feb; 38(2):145-9. PubMed ID: 10225670
[TBL] [Abstract][Full Text] [Related]
28. Pheochromocytoma in von Hippel-Lindau disease and neurofibromatosis type 1.
Opocher G; Conton P; Schiavi F; Macino B; Mantero F
Fam Cancer; 2005; 4(1):13-6. PubMed ID: 15883705
[TBL] [Abstract][Full Text] [Related]
29. Pheochromocytoma-associated syndromes: genes, proteins and functions of RET, VHL and SDHx.
Gimm O
Fam Cancer; 2005; 4(1):17-23. PubMed ID: 15883706
[TBL] [Abstract][Full Text] [Related]
30. Von Hippel-Lindau gene alterations in sporadic benign and malignant pheochromocytomas.
Dannenberg H; De Krijger RR; van der Harst E; Abbou M; IJzendoorn Y; Komminoth P; Dinjens WN
Int J Cancer; 2003 Jun; 105(2):190-5. PubMed ID: 12673678
[TBL] [Abstract][Full Text] [Related]
31. Molecular characterization and ophthalmic investigation of a large family with type 2A Von Hippel-Lindau Disease.
Allen RC; Webster AR; Sui R; Brown J; Taylor CM; Stone EM
Arch Ophthalmol; 2001 Nov; 119(11):1659-65. PubMed ID: 11709017
[TBL] [Abstract][Full Text] [Related]
32. Occurrence of MEN 2a in familial Hirschsprung's disease: a new indication for genetic testing of the RET proto-oncogene.
Decker RA; Peacock ML
J Pediatr Surg; 1998 Feb; 33(2):207-14. PubMed ID: 9498388
[TBL] [Abstract][Full Text] [Related]
33. Von Hippel-Lindau syndrome. A pleomorphic condition.
Friedrich CA
Cancer; 1999 Dec; 86(11 Suppl):2478-82. PubMed ID: 10630173
[TBL] [Abstract][Full Text] [Related]
34. Mutations of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours, and hirschsprung disease.
Eng C; Mulligan LM
Hum Mutat; 1997; 9(2):97-109. PubMed ID: 9067749
[TBL] [Abstract][Full Text] [Related]
35. Clinical characteristics and genetic screening of an extended family with MEN2A.
Algün E; Abaci N; Kösem M; Kotan C; Köseoğlu B; Boztepe H; Sekeroğlu R; Aslan H; Topal C; Ayakta H; Uygan I; Alagöl F; Erginel-Unaltuna N; Aksoy H
J Endocrinol Invest; 2002; 25(7):603-8. PubMed ID: 12150334
[TBL] [Abstract][Full Text] [Related]
36. Absence of mutations in the MEN2A region of the ret proto-oncogene in non-MEN 2A phaeochromocytomas.
Chew SL; Lavender P; Jain A; Weber A; Ross RJ; Wass JA; Besser GM; Clark AJ
Clin Endocrinol (Oxf); 1995 Jan; 42(1):17-21. PubMed ID: 7889627
[TBL] [Abstract][Full Text] [Related]
37. Somatic and MEN 2A de novo mutations identified in the RET proto-oncogene by screening of sporadic MTC:s.
Zedenius J; Wallin G; Hamberger B; Nordenskjöld M; Weber G; Larsson C
Hum Mol Genet; 1994 Aug; 3(8):1259-62. PubMed ID: 7987299
[TBL] [Abstract][Full Text] [Related]
38. Genotype-phenotype correlation in von Hippel-Lindau syndrome.
Friedrich CA
Hum Mol Genet; 2001 Apr; 10(7):763-7. PubMed ID: 11257110
[TBL] [Abstract][Full Text] [Related]
39. [Germline mutations of the ret proto-oncogene in Chilean patients with hereditary and sporadic medullary thyroid carcinoma].
Wohllk N; Becker P; Youlton R; Cote GJ; Gagel RF
Rev Med Chil; 2001 Jul; 129(7):713-8. PubMed ID: 11552438
[TBL] [Abstract][Full Text] [Related]
40. A variety of phenotype with R161Q germline mutation of the von Hippel-Lindau tumor suppressor gene in Japanese kindred.
Iida K; Okimura Y; Takahashi K; Inomata S; Iguchi G; Kaji H; Chihara K
Int J Mol Med; 2004 Mar; 13(3):401-4. PubMed ID: 14767570
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
